현대ADM
Financials
Valuation Metrics
현대ADM's Market Cap is ₩4158B. At end of 2025 it was ₩1478B. Ranked #527 of 2,421 in KR market (top 22%), #204 of 1,640 on KOSDAQ (top 12%), #56 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 415.78B KRW | KR#527/2,421 Sec#56/231 |
| Revenue | 8.34B KRW | KR#2,304/2,421 Sec#182/231 |
| Net Income | -16.36B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 34.14B KRW | KR#2,311/2,421 Sec#214/231 |
| Net Assets | 22.94B KRW | KR#2,255/2,421 Sec#210/231 |
| Employees | 159 | KR#1,273/2,421 Sec#104/231 |
| Value | ||
| P/B | 18.13x | KR#2,400/2,421 Sec#223/231 |
| P/S | 49.83x | KR#2,373/2,421 Sec#196/231 |
| FCF Yield | -1.26% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -71.34% | KR#2,323/2,421 Sec#211/231 |
| ROA | -47.94% | KR#2,361/2,421 Sec#215/231 |
| Op. Margin | -80.30% | KR#2,289/2,421 Sec#169/231 |
| Revenue Growth | -6.48% | KR#1,828/2,421 Sec#173/231 |
| Earnings Growth | -274.47% | KR#1,266/2,421 Sec#88/231 |
| Financial Health | ||
| Debt Ratio | 48.83% | KR#945/2,421 Sec#108/231 |
| Total Debt | 5.00B KRW | KR#1,786/2,421 Sec#170/231 |
| FCF | -5.22B KRW | KR#1,505/2,421 Sec#117/231 |
| Cash | 424.3M KRW | KR#2,369/2,421 Sec#225/231 |
| Current Ratio | 0.49x | KR#2,151/2,421 Sec#208/231 |
| Performance | ||
| 1Y Return | 172.65% | KR#60/2,421 Sec#2/231 |
| 1M Return | 70.38% | KR#31/2,421 Sec#4/231 |
| From 52W High | -68.88% | KR#2,168/2,421 Sec#185/231 |
| 1Y MDD | -81.53% | KR#2,321/2,421 Sec#216/231 |
| Trading | ||
| Volume | 1,019,449 shares | KR#135/2,421 Sec#10/231 |
| Trading Value | 6.63B KRW | KR#315/2,421 Sec#28/231 |
| Foreign Own. | 1.17% | KR#1,958/2,421 Sec#192/231 |
| Per Share | ||
| EPS | -256 KRW | KR—/2,421 Sec—/231 |
| BPS | 359 KRW | KR#2,404/2,421 Sec#228/231 |
Company Info
Established in 2003, this Contract Research Organization (CRO) was acquired by Hyundai Bioscience in 2024. It holds exclusive rights to drug delivery technology and provides comprehensive services to pharmaceutical companies and bio-ventures, including clinical trial design, monitoring, and data management. The company is developing breast and lung cancer treatments using inorganic material-based drug delivery system technology. It aims to become a global specialized oncology company through digital clinical trials leveraging AI, Big Data, and remote monitoring. Hyundai ADM is headquartered in Jongno-gu, Seoul.